

Department of Psychiatry and Neurosciences

USF Health · College of Medicine

Office of the Chair - Week of August 22-26, 2011

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Meetings

Thursday	08/25/11	8:00 a.m.	Call Center Meeting
			<u>Resident Lectures:</u>
		8:00 a.m.	PGY-2 – “Depression in the General Medical Setting” Dr. Barbara Lubrano
			PGY-3, PGY-4 – “Half and Half Buprenorphine Course” Dr. Michael Sheehan
			CHILD – “Psychopharm Case Conference” Dr. Amit Razdan
		9:00 a.m.	PGY-2 – “Introduction to Psychotherapy” Dr. Robert Fernandez
			PGY-3, PGY-4 – “Half and Half Buprenorphine Course” Dr. Michael Sheehan
			CHILD – “Depression” Dr. Amit Razdan
		10:00 a.m.	PGY-3, PGY-4 – “Half and Half Buprenorphine Course” Dr. Michael Sheehan
			CHILD – “Depression” Dr. Amit Razdan
		11:00 a.m.	Residents’ Meeting
		12:00 noon	NO GRAND ROUNDS
Friday	08/26/11		<u>Medical Student Lectures</u>
		8:00 a.m.	“Mood Disorders” Dr. Barbara Lubrano
		10:00 a.m.	“Thought Disorders” Dr. Glenn Catalano
		1:00 p.m.	“Seizures” Drs. Benbadis/Frontera/Bozorg
		2:00 p.m.	“Sleep Disorders” Dr. Ali Bozorg

In The Know!

Happy Birthday wishes to Scott Barnett/August 22nd and Dr. Mariann Suarez/August 22nd.

Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as adjunctive therapy in patients with major depression associated with Bipolar I Disorder. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator – Carlos Santana, M.D.

Schizophrenia PRIDE Study – Jail Recidivism

A 15- month open label study comparing oral antipsychotic treatment to paliperidone palmitate injections in delaying arrest recidivism in adults with Schizophrenia. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 90 days prior to screening. Subjects receive antipsychotic medications at no charge. Principal Investigator – Jean Fils, M.D.

NEW AUTISM STUDY

We are happy to announce USF Psychiatry's participation in a Phase 4, Safety and Efficacy study of Aripiprazole in the long-term maintenance treatment of children and adolescents 6-17 years of age with irritability associated with Autistic Disorder. The study is divided into three phases – a 7-42 day screening period, a 13-26 week single-blind phase, and a 16-week double-blind, placebo-controlled phase. Kids ages 6-17 with autism are eligible to screen for this study. Call 813-974-2832 for more information. Principal Investigator – Mike Bengtson, MD.

Now Open and Enrolling – ADHD Aggression Study

Kids between the ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial . Children must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator – Mike Bengtson, MD.

Coming Soon - Bipolar I in Teens

This study is a 3- week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder who are currently experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator - Mike Bengtson, MD.

Study-related care will include a comprehensive diagnostic exam, physical exam, laboratory testing, ECG and frequent doctor visits, as well as investigational medication, all at no charge. This is a placebo controlled trial and all participants who complete the study will have the option to enroll in an open label 6 month extension study. Enrolled patients will be compensated for time and travel.

<http://health.usf.edu/medicine/psychiatry/research/index.htm>